Back to Search
Start Over
Evaluation of Prescription Practices of Domperidone in Parkinson’s Disease: A Cross Sectional Study Among French Neurologists
- Source :
- CNS Drugs. 34:1267-1274
- Publication Year :
- 2020
- Publisher :
- Springer Science and Business Media LLC, 2020.
-
Abstract
- Domperidone is used to treat gastrointestinal symptoms in patients with Parkinson’s disease. Because of an increased risk of cardiac adverse events, the European Medicines Agency has issued recommendations restricting its use mainly in terms of age, dose, and treatment duration. The aim of this study was to investigate current prescription practices of domperidone in Parkinson’s disease among French neurologists. A cross-sectional study based on a questionnaire was conducted among French neurologists from Parkinson’s disease expert centers from the French NS-Park/FCRIN network, general hospitals, and private practice. Among the 253 neurologists who completed the questionnaire, 86 (34%) were physicians from expert centers and 167 (66%) were from other healthcare settings; 209 (83%) were aware of recommendations restricting domperidone use. The majority of neurologists (92%) declared prescribing domperidone regardless of the age of the patients. Sixty-one percent of neurologists prescribed domperidone beyond 7 days in newly diagnosed patients, 33% in patients with orthostatic hypotension, and 79% in patients receiving continuous apomorphine treatment. They did not follow the recommendation on posology in newly diagnosed patients (7% of neurologists), patients with orthostatic hypotension (10%), and patients receiving continuous apomorphine therapy (25%). Finally, only 58% of neurologists declared taking specific precautions before prescribing domperidone. These findings show most French neurologists who responded to our questionnaire do not fully follow the restrictions on domperidone use, particularly in terms of treatment duration, and in patients receiving continuous apomorphine treatment. This may reflect the unmet need to prevent nausea in patients with Parkinson’s disease treated with dopaminergic drugs, particularly continuous apomorphine therapy.
- Subjects :
- Adult
Male
medicine.medical_specialty
Pediatrics
Time Factors
Neurology
Apomorphine
Nausea
Cross-sectional study
03 medical and health sciences
Orthostatic vital signs
0302 clinical medicine
mental disorders
medicine
Humans
Pharmacology (medical)
Neurologists
Practice Patterns, Physicians'
Medical prescription
Adverse effect
Dose-Response Relationship, Drug
business.industry
Age Factors
Parkinson Disease
Middle Aged
Domperidone
nervous system diseases
030227 psychiatry
Psychiatry and Mental health
Cross-Sectional Studies
Private practice
Health Care Surveys
Dopamine Antagonists
Female
France
Guideline Adherence
Neurology (clinical)
medicine.symptom
business
030217 neurology & neurosurgery
medicine.drug
Subjects
Details
- ISSN :
- 11791934 and 11727047
- Volume :
- 34
- Database :
- OpenAIRE
- Journal :
- CNS Drugs
- Accession number :
- edsair.doi.dedup.....ced70a650171deee7f064aa29ce3a3e7